Print Page | Contact Us | Sign In | Join FSN
2021 FSN Annual Meeting Exhibitors and Sponsors
Share |

Platinum

 

 

 

 

 

 

 

 

Gold

 

 

 

   
     
     
     

Silver

   

   
     

Bronze

   

   
     


   
     


 
     

Fresenius Kidney Care

Fresenius Kidney Care is the largest manufacturer of Hemodialysis products and Peritoneal Dialysis products, including the 2008 T Dialysis machines, Bloodlines, Dialyzers, Concentrate, Critline - Blood Volume Monitors and Peritoneal Dialysis machines, Lines and Solutions in the U.S. 

   
     

 

  

   
     

OPKO Renal Division

OPKO Renal Division focuses on developing proprietary products to treat secondary hyperparathyroidism associated with chronic kidney disease. OPKO’s expertise in Vitamin D biochemistry, metabolism and physiology, combined with its experience in successfully bringing Vitamin D therapeutics to market uniquely positions the Renal Division to improve the lives of CKD patients.

   
     

Retrophin

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options.

         
     

 

 

              

Exhibitors: Class 1

   
   
   

 

   
     

Amicus Therapeutics

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. 

  
   

   
     

   
     

   
     

 

   
     

   
     

 

   
     

 

 
              
     

   
     
Relypsa     
     

Retrophin

Retrophin is a biopharmaceutical company dedicated to identifying, developing and delivering life-changing therapies to people living with rare diseases, who have few, if any, treatment options.

       
     

   
     

   
     

Tricida, Inc.

Tricida, Inc., is focused on the development and commercialization of its drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is believed to accelerate the progression of CKD, increase the risk of muscle wasting, and cause the loss of bone density.  

  
   

 
   
 

Exhibitors: Class 2

   

 

            

 

 
   
   

 

 

   
     
     

   
     


    
     

 

   
     
     
   
   

 

  
     

   
     

 

   




FLORIDA SOCIETY OF NEPHROLOGY
1215 E. Robinson Street, Orlando, FL 32801
Phone: 813-909-0450  |  Fax: 813-949-8994